灵葜四君颗粒在胃癌化疗中对骨髓的保护作用

[目的]探讨灵葜四君颗粒在胃癌化疗中对骨髓的保护作用。[方法]120例胃癌术后患者随机分为治疗组(灵葜四君颗粒加化疗)和对照组(单纯化疗),各60例。连续观察2个疗程,比较2组的完成率、白细胞(WBC)下降发生率、2组化疗后骨髓毒性分级情况、粒细胞集落刺激因子(rhG-CSF)用量及WBC治疗后恢复至正常所需要的时间。[结果]连续2个疗程的完成率治疗组为93.33%,高于对照组68.33%(P<0.01);WBC下降发生率治疗组为31.67%,明显低于对照组的71.67%(P<0.01);2组化疗后治疗组全血WBC下降发生明显少于对照组,并且治疗组无Ⅲ、Ⅳ度骨髓抑制发生;治疗组Ⅰ、Ⅱ、Ⅲ、Ⅳ度WBC减少后WBC恢复至正常需要的时间与对照组比较明显缩短(P<0.01);rhG-CSF人均用量(支)治疗组(3.58±0.94)较对照组(6.72±0.73)明显减少(P<0.01)。[结论]灵葜四君颗粒对胃癌化疗骨髓抑制有很好的防治作用,并可以减少rhG-CSF用量,有一定的经济效益。     

不同病理分型胃癌患者放疗前后T细胞亚群及NK细胞的变化

目的探讨胃癌根治术后放疗对外周血T细胞亚群及NK细胞的影响及不同胃癌病理分型放疗前后T细胞亚群及NK细胞的变化。方法选择该院2011年6月至2013年6月收治的55例胃癌手术患者,另选取同期35例健康人作为对照组,采用流式细胞术测定外周血T细胞亚群和NK细胞相对比例的变化,比较不同病理类型胃癌患者放疗前后T细胞亚群和NK细胞变化趋势。结果胃癌患者根治术后放疗前外周血CD3+、CD4+、CD8+T细胞和NK细胞的比例接近对照组(P>0.05);放疗后,胃癌患者外周血CD3+、CD4+、CD8+T细胞和NK细胞的比例显著降低(P<0.05)。不同病理类型的胃癌患者,放疗前后其外周血T细胞亚群及NK细胞水平存在不同程度的变化,其中乳头状腺癌患者放疗后CD8+T细胞、NK细胞比例减少(P<0.05),但是CD3+T细胞、CD4+T细胞没有变化;管状腺癌患者放疗后CD3+T细胞和CD4+T细胞和NK细胞比例显著降低(P<0.05),CD8+T细胞没有变化;印戒细胞癌和未分化癌患者的T细胞亚群水平显著下降(P<0.05),但是NK不受影响;黏液腺癌患者放疗前后外周血T细胞亚群及NK细胞水平均没有变化。结论手术后放疗能够抑制胃癌患者的免疫功能,放疗前后不同病理类型的胃癌患者外周血T细胞亚群及NK细胞变化各不相同。应该根据不同的病理类型实行相应的增强免疫功能措施。     

扶正抑瘤饮对消化道恶性肿瘤患者细胞免疫功能的影响

目的 :观察扶正抑瘤饮对接受化疗的消化道肿瘤患者细胞免疫功能的影响。方法 :6 0例中晚期消化道肿瘤患者随机分成治疗组 (化疗加中药 )、对照组 (单纯化疗 ) ,在 1个疗程化疗前后分别检测患者外周血 T淋巴细胞亚群、可溶性白细胞介素 - 2受体 (s IL- 2 R)含量 ,并与正常组作比较。结果 :化疗前与正常组相比 ,治疗组、对照组外周血 CD4 细胞比例均减少 ,CD 8细胞比例升高 ,CD 4/ CD 8比值降低 (P <0 .0 5 ) ;s IL- 2 R含量明显升高 (P <0 .0 1)。化疗后与化疗前相比 ,对照组外周血 CD 4细胞比例下降 ,CD 8细胞比例升高 ,CD 4/ CD 8比值下降 ,外周血s IL - 2 R含量升高 ;而治疗组 CD 4细胞比例明显升高 ,CD 4/ CD 8比值上升 ,s IL - 2 R含量下降 ,差异均有显著性意义(P <0 .0 5 ) ;结论 :扶正抑瘤饮可显著改善化疗引起的免疫功能低下     

胃癌中医证型与细胞免疫因子关系的探讨

[目的]通过检测外周静脉血T细胞亚群及可溶性白细胞介素2受体（SIL-2R）在胃癌不同证型中的变化,探讨胃癌证型与细胞免疫功能关系。[方法]采用碱性磷酸酶抗碱性磷酸酶和ELISA法检测113例胃癌患者外周血T细胞亚群及SIL-2R水平,对不同证型与其变化的关系进行分析,并与30例对照者比较。[结果]胃癌虚证患者外周血总T细胞与对照组比较差异有统计学意义（P〈0．05）。胃癌实、虚证患者与对照者SIL-2R比较差异有统计学意义（P〈0．01）,实、虚证患者之间SIL-2R比较差异有统计学意义（P〈O．05）。CD4^＋T细胞以肝胃不和型〉瘀毒内阻型〉痰湿凝结型〉胃热伤阴型〉脾胃虚寒型〉气血双亏型,而CD8^＋T细胞与之相反,呈下降趋势。[结论]不同中医证型胃癌患者细胞免疫功能依肝胃不和型、瘀毒内阻型、痰湿凝结型、胃热伤阴型、脾胃虚寒型、气血双亏型次序逐渐下降,提示辨证分型与患者细胞免疫功能密切相关。     

DC、CIK白体回输对化疗后胃癌患者T淋巴细胞亚群及NK细胞的影响

目的研究树突状细胞（DC）与细胞因子诱导的杀伤细胞（CIK）自体回输对化疗后胃癌患者T淋巴细胞亚群及NK细胞的影响。方法将92例胃癌患者随机分为观察组及对照组各46例,两组均行常规化疗,观察组于化疗结束后1个月实施DC、CIK自体回输治疗,治疗时间〉2个疗程。采集两组化疗前后及观察组DC和CIK自体回输之后4周的外周血,以流式细胞仪对外周血T淋巴细胞亚群及NK细胞进行检测。结果两组化疗后CD;、CD4＋、CD4＋／cDf、NK水平均明显降低,观察组DC与CIK回输后CD^＋3、CD^＋4、CD^＋4／co^＋8、NK水平明显高于本组及对照组化疗后,P均〈0．05。结论化疗后胃癌患者DC、CIK白体回输后CD^＋3、CD4^＋4、CD^＋4／CD^＋8、NK水平升高,即细胞免疫功能得到改善。     

肺心病患者T细胞亚群,sIL—2R及NK细胞活性的观察

我们测定了肺心病急性加重期患者外周血T细胞亚群、NK细胞活性及血清中可溶性白细胞介素2受体（sIL-2R）水平。结果显示：患者外用血CD 4细胞降低，CD 8细胞升高，CD 4／CD 8比值降低·NK细胞活性下降,血清SIL－2R水平升高，表明患者存在细胞免疫功能异常。提高免疫功能列为该病治疗的重要措施。     

胃癌患者细胞免疫功能的变化及意义

应用流式细胞技术检测胃癌患者外周血T细胞亚群分布和自然杀伤（NK）细胞活性。结果与对照组相比,胃癌患者外周血CD3^＋、CD4^＋、NK细胞比例降低,CD8^＋细胞比例升高,CD4^＋/CD8^＋＋下降,而且升高或降低的程度与Borrm an分型和有无淋巴结转移相关。认为细胞免疫与胃癌发生、发展及预后密切相关,外周血T细胞亚群和NK细胞活性可作为监测胃癌病情变化的重要指标。     

射频消融术对肝细胞肝癌患者特异性T淋巴细胞活性的影响

目的观察射频消融治疗对肝细胞肝癌患者特异性T淋巴细胞活性的影响。方法20例肝细胞肝癌患者随机分为两组:对照组(n=10)和射频组(n=10),所有患者均给予统一肝动脉插管化疗栓塞治疗(TACE),射频组加用射频消融术(RFA)。在治疗前、治疗后4w、8w分别采血样本。用APAAP法和LDH释放改良法分别检测外周血T细胞亚群及NK细胞活性。结果治疗前两组患者外周血T细胞亚群及NK细胞活性无显著差别(P>0.05);对照组治疗后4w外周血CD3、CD4、NK细胞活性略有升高,CD8略有下降,与治疗前相比无显著差别(P>0.05);射频组治疗后4w外周血CD3、CD4明显升高,CD8较前下降,CD4/CD8比值升高,与对照组相比,存在显著差异(P<0.05);与治疗前相比也存在差别(P<0.01),这种趋势一直持续到治疗后8w。结论RFA治疗后原发性肝癌患者显示明显T细胞刺激反应CD3、CD4,T细胞活性急剧增加。     

TACE联合肿瘤间质对介入治疗肝细胞癌患者免疫功能的影响

目的探讨单纯经肝动脉化疗栓塞(TACE)联合肿瘤间质对介入治疗肝细胞癌(HCC)患者免疫功能的影响。方法 90例HCC患者随机分为对照组和实验组,对照组行TCAE治疗,实验组行TCAE联合经皮肝瘤内注射碘油化疗药物进行肿瘤间质治疗,另选取体检健康者为空白组45例。分别采用流式细胞技术及酶联免疫吸附(ELISA)法测定患者治疗前、治疗后1、2、3、4 w外周血T淋巴细胞亚群(CD3~+、CD4~+、CD8~+)和血清可溶性白细胞介素-2受体(SIL-2R)水平。结果治疗前实验组和对照组T淋巴细胞亚群和SIL-2R水平与空白组比较差异显著(P<0.05);治疗1、2、3、4 w后CD3~+、CD4~+及CD4~+/CD8~+比值明显升高,CD8~+和SIL-2R水平明显下降(P<0.05)。治疗1、2、3 w后,对照组与实验组CD8~+和CD4~+/CD8~+比值无统计学差异(P>0.05),治疗4 w后CD4~+/CD8~+有统计学差异(P<0.05),治疗1、2、3、4 w后,对照组和实验组CD3~+、CD4~+和SIL-2R水平均有统计学差异(P<0.05)。实验组不良反应较对照组轻。结论 TACE联合肿瘤间质能够明显提高患者的免疫能力,改善患者的免疫抑制,且能够弥补单纯使用TACE治疗的不足。     

非霍奇金淋巴瘤患者化疗前后T淋巴细胞亚群变化及临床意义

目的探讨非霍奇金淋巴瘤(NHL)患者化疗前后外周血T淋巴细胞亚群及NK细胞的变化及临床意义。方法选取初诊病理确诊为NHL的患者60例作为NHL组,同期健康体检者60名为对照组,采用流式细胞术检测两组对象T细胞亚群及NK细胞的表达情况,比较对照组与NHL组不同病理类型患者化疗前后表达的差异。结果 NHL患者化疗前CD3+、CD4+、NK细胞百分比显著低于对照组(P0.05);CD8+、调节性T细胞(Treg细胞)百分比显著高于对照组(P0.05)。化疗后,NHL患者CD3+、CD4+、NK细胞百分比显著增高(P0.05);CD8+、调节性T细胞(Treg细胞)百分比显著降低(P0.05)。B-NHL组患者CD3+、CD4+、CD8+细胞百分比显著高于Treg组患者(P0.01);NK、Treg细胞百分比显著低于Treg组患者(P0.01)。化疗前,化疗有效和无效患者T淋巴细胞亚群及NK细胞表达情况比较差异无统计学意义(P0.05)。化疗后,化疗有效患者T淋巴细胞和NK细胞表达情况明显改善(P0.05),而化疗无效组患者无明显变化(P0.05);化疗有效患者CD3+、CD4+、Treg细胞百分比显著高于化疗无效患者(P0.05或0.01)。结论细胞免疫功能低下是非霍奇金淋巴瘤发病的一个重要因素,不同病理类型患者外周血T细胞亚群及NK细胞表达情况以及化疗效果不同,检测患者T细胞亚群及NK细胞表达情况有助于判断治疗效果和预测预后。     

He Jie Tang in the treatment of chronic hepatitis B patients

AIM: To explore the effect of He Jie Tang (decoction for medication) on serum levels of T lymphocyte subsets, NK cell activity and cytokines in chronic hepatitis B patients. METHODS: Eighty-five patients with chronic hepatitis B were divided randomly into two groups. Fifty patients in group Ⅰ were treated with He Jie Tang (HJT) and 35 patients in group Ⅱ were treated with combined medication. The levels of T-lymphocyte subsets (CD3+, CD4+, CD8+), NK cell activity, cytokines (TNF-α, IL-8, sIL-2R) were observed before and after the treatment. Another 20 normal persons served as group 3. RESULTS: The level of CD4+ cells and NK cell activity were lower, whereas the level of CD8+ cells in patients was higher than that in normal persons (t = 2.685, 3.172, and 2.754 respectively; P<0.01). The levels of TNF-α, IL-8, and sIL-2R in chronic hepatitis B patients were higher than those in normal persons (t = 3.526, 3.170, and 2.876 respectively; P<0.01). After 6 months of treatment, ALT, AST, and TB levels in the two groups were obviously decreased (t = 3.421, 3.106, and 2.857 respectively; P<0.01). The level of CD4+ cells and NK cell activity were increased whereas the level of CD8+ cells decreased (t = 2.179, 2.423, and 2.677 respectively; P<0.05) in group Ⅰ. The levels of TNF-α, IL-8, and sIL-2R in group I were decreased significantly after the treatment (t = 2.611, 2.275, and 2.480 respectively; P<0.05) but had no significant difference in group Ⅱ after the treatment (t = 1.906, 1.833, and 2.029 respectively; P>0.05). The total effective rate had no significant difference between the two groups (X2 = 2.882, P>0.05) but the markedly effective rate was significantly different between the two groups (X2 = 5.340, P<0.05). CONCLUSION: HJT is effective in treating chronic hepatitis B. HJT seems to exert its effect by improving the cellular immune function and decreasing inflammatory cytokines in chronic hepatitis B patients. The function of HJT in protecting liver function in the process of eliminating virus needs to be further studied.     

Therapeutic efficacy of high-dose vitamin C on acute pancreatitis and its potential mechanisms

AIM: To observe the therapeutic efficacy of high-dose Vitamin C 0/it. C) on acute pancreaUtis (AP), and to explore its potential mechanisms. METHODS: Eghty-four AP patients were divided into treatment group and control group, 40 healthy subjects were taken as a normal group, In the treatment group, Vit. C (10 g/day) was given intravenously for 5 days, whereas in the control group, Vit. C (1 g/day) was given intravenously for 5 days. Symptoms, physical signs, duration of hospitalization, complications and mortality rate were monitored. Meanwhile, serum amylase, urine amylase and leukocyte counts were also determined. The concentration of plasma vitamin C (P-VC), plasma lipid peroxide (P-LPO), plasma vitamin E (P-VE), plasma β-carotene (P-β-CAR), whole blood glutathione (WB-GSH) and the activity of erythrocyte surperoxide dimutase (E-SOD) and erythrocyte catalase (E-CAT) as well as T lymphocyte phenotype were measured by spectrophotometry in the normal group and before and after treatment with Vit. C in the treatment and the control group. RESULTS: Compared with the normal group, the average values of P-VC, P-VE, P-β-CAR, WB-GSH and the activity of E-SOD and E-CAT in AP patients were significantly decreased and the average value of P-LPO was significantly increased, especially in severe acute pancreatitis (SAP) patients (P&lt;0.05. P-VC, P=0.045; P-VE, P=0.038; P=0.041;P-β-CAR, P=0.046; WB-GSH, P=0.039; E-SOD, P=0.019;E-CAT, P=0.020; P-LPO, P=0.038). Compared with the normal group, CD3 and CD4 positive cells in AP patients were significantly decreased. The ratio of CD4/CD8 and CD4 positive cells were decreased, especially in SAP patients (P&lt;0.05. CD4/CDs, P=0.041; CD4, P =0.019). Fever and vomiting disappeared, and leukocyte counts and amylase in urine and blood become normal quicker in the treatment group than in the control group. Moreover, patients in treatment group also had a higher cure rate, a lower complication rate and a shorter in-ward days compared with those in he control group. After treatment, the average value of P-VC was significantly higher and the values of SIL-2R, TNF-α, IL-6 and IL-8 were significantly lower in the treatment group than in the control group (P&lt;0.05 P-VC, P=0.045; SIL-2R, P=0.012; TNF-α, P=0.030; IL-6, P=0.015,and IL-8, P=0.043). In addition, the ratio of CDJCD8 and CD4 positive cells in the patients of treatment group were significantly higher than that of the control group after treatment (P&lt;0.05. CD4/CDs, P =0.039; CD4, P=0.024). CONCLUSION: High-dose vitamin C has therapeutic efficacy on acute pancreatitis. The potential mechanisms include promotion of anti-oxidizing ability of AP patients, blocking of lipid peroxidation in the plasma and improvement of cellular immune function.     

化疗对胃癌患者免疫功能的影响

背景：化疗药物可杀灭或抑制胃癌患者的肿瘤细胞，同时亦影响患者机体的免疫状态。分析胃癌患者化疗前后免疫状态的变化有助于准确实施化疗和综合治疗。目的：探讨化疗对胃癌患者免疫功能的影响。方法：共63例接受化疗的胃癌患者入选，化疗前后分别应用流式细胞仪和酶联免疫吸附测定（ELISA）检测外周血T细胞亚群和血清可溶性白细胞介素-2受体（sIL-2R）水平，并设健康者作为正常对照组。结果：胃癌患者化疗前CD3^＋、CD4^＋T细胞数以及CD4^＋／CD8^＋比值显著低于正常对照组（P〈0．05），血清sIL-2R水平显著升高（P〈0．05）。化疗后1周胃癌患者CD3^＋、CD4^＋T细胞数、CD4^＋／CD8^＋比值较化疗前显著降低（P〈0．05），血清sIL-2R水平显著升高（P〈0．05）；化疗后3周，上述指标逐渐恢复。与化疗前水平相比无明显差异，但与正常对照组相比差异仍有统计学意义（P〈0．05）。化疗过程中最常见的不良反应为恶心、呕吐（68.3％）和骨髓抑制（46．0％）。结论：胃癌患者在短期化疗后出现的免疫功能抑制需3周以上才能明显恢复。应于化疗早期使用免疫增强调节剂，以利于实施有效的综合治疗。     

ITP患儿的白细胞介素2受体及NK细胞的研究

采用双抗夹心ELISA、APAAP桥联酶标法、MTT比色法检测了34例ITP患儿的血清可溶性白介素2受体（sIL-2R）外周血单个核细胞（PBMC）经PHA刺激后膜白介素2受体（mIL－2R）的表达、T淋巴细胞亚群以及自然杀伤（NK）细胞活性。结果：ITP患儿血清sIL－2R水平升高，mIL－2R的表达和NK活性显著降低；血清sIL－2R水平与NK活性、CD4 ／CD8 比值是负相关，与疾病严重程度和疗效密切相关。提示sIL－2R可作为监测病情、观察疗效的敏感指标；在纠正ITP的免疫调节紊乱中应充分考虑到细胞因子受体异常这个环节。     

Immunomodulatory effects of blood letting cupping therapy in patients with rheumatoid arthritis

This study was carried out in order to evaluate the efficiency of blood-letting cupping (BLC) therapy as a complementary therapy in management of rheumatoid arthritis (RA) and to investigate its modulatory effects on natural killer cells (NK) and soluble interleukin-2 receptor (SIL-2R). Two groups of RA patients diagnosed according to American Rheumatology Association were included: Group I included 20 patients who received the conventional medicinal therapy of RA, Group II included 30 patients who received combined conventional and BLC therapy. Ten age and sex matched normal controls were also included, as group III. Visual analogue score (VAS), tender joint count (TJC), swollen joint count (SJC), disease activity scores (DAS), laboratory markers of disease activity [erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), Rheumatoid factor (RF)] were evaluated on 3 successive months, NK cell (%) measured by flowcytometry and SIL-2R concentrations measured by ELISA were also assessed. After one month of combined therapy there was significant (P < 0.001) reduction in VAS (5.16 +/- 0.28), TJC (11.62 +/- 1.03), SJC (10.13 +/- 1.02) and DAS (5.35 +/- 0.14). Early and marked reductions in laboratory markers of disease activity (26.90 +/- 3.68) for CRP, (51.46 +/- 6.06) for RF and (40.56 +/-3.36) for ESR were also detected as compared to base line, while the effects of conventional therapy appeared late after 3 months of treatment. Conventional therapy induced significant depression in white blood cell (WBC %) (p < 0.001) whereas combined therapy induced marked (p < 0.001) elevation since the first month (8.44 +/- 1.58) compared to base line (6.94 +/- 1.58). There was a significant (P < 0.05) lowering in NK cell (%) with conventional therapy while combined therapy induced significant (P < 0.001) increase (11.33 +/- 0.4.7) compared to base line level (8.50 +/- 0.46). Additionally, combined therapy resulted in marked reduction (P < 0.001) in SIL-2R conc. after 3 months of treatment (1790 +/- 68.11) compared to base line (2023 +/- 92.95), while insignificant reduction was detected with the conventional therapy. The improvement rate (%) of clinical, laboratory cellular & immunological parameters were significantly higher with combined therapy than with conventional therapy. Moreover, strong positive correlations (p < 0.0001) were detected between SIL-R conc. and clinical parameters VAS (r = 0.890), TJC (r = 0.905), SJC (r = 0.872) and DAS (r = 0.923) and also between SIL-R conc. and ESR (r = 0.973), CRP (r = 0.933), RF (r = 0.941), while a strong negative correlation was found with NK count cell % (r = 0.927). In conclusion, BLC therapy combined with conventional therapy may improve the clinical condition of patients with RA. It has modulatory effects on the innate (NK %) and adaptive cellular (SIL-2R conc.) immune responses that could be used as monitoring tools for disease activity and prognosis.     

Decrease in CD3-negative-CD8dim(+) and Vdelta2/Vgamma9 TcR+ peripheral blood lymphocyte counts,low perforin expression and the impairment of natural killer cell activity is associated with chronic hepatitis C virus infection

BACKGROUND/AIMS: As chronic hepatitis C virus (HCV) infection is associated with impaired natural killer (NK) cell cytotoxicity, we examined the phenotypes and perforin expression of peripheral blood lymphocytes, as well as the effect of interferon-alpha2b (IFN-alpha2b) therapy. METHODS: Thirty-three patients had chronic hepatitis C, and of them 12 had been on IFN-alpha2b treatment. Eleven individuals had been treated earlier with IFN-alpha2b and completely cured, and eight were HCV carriers with persistently normal serum alanine aminotransferase. Three-colour flow cytometry was used to measure the percentage of CD3(+/-)CD8+, CD3+CD4+, gammadeltaTcR+, Vdelta2 TcR+, Vgamma9 TcR+, Vdelta1 TcR+, CD3-CD16+, CD3-CD56+, CD19+ and perforin-positive cells. NK cell activity was assessed by single cell cytotoxic and flow cytometric assay. RESULTS: Patients with chronic hepatitis C showed an impaired NK cytotoxicity, decreased percentage of CD3-negative-CD8dim-positive (NK subtype) and Vgamma9/Vdelta2 TcR+ as well as perforin-positive T lymphocytes, compared to controls and to those who were cured from HCV infection. IFN-alpha2b increased NK cell cytotoxicity and the percentage of perforin-positive lymphocytes. CONCLUSIONS: Our findings suggest that in chronic HCV infection a decreased percentage of CD3(-)CD8+, Vgamma9/Vdelta2 TcR+ and perforin-positive T cells and simultaneous decreased peripheral NK activity may contribute to the impaired cellular immune response and the chronicity of the disease.     

不同时期卡介苗免疫治疗对结核病大鼠疗效和CD4+CD8+双阳(DP)T细胞的影响

目的探讨不同时期给予卡介苗(BCG)免疫治疗对结核病化疗效果和T细胞严群的影响。方法80只PPD皮试阴性SD大鼠随机分成(1)化疗开始同步加BCG治疗组;(2)化疗1月后加BCG治疗组;(3)单纯化疗对照组;(4)模型效果判断组。各组于实验开始接受结核杆菌(Mtb)攻毒;第1个月末处死模型效果判断组全部大鼠作病理学和结核杆菌细菌学检查,其他各组于第1个月末接受抗结核化疗,其中第1组化疗开始加用BCG治疗,第2组化疗1个月后加用BCG治疗。观察各组大鼠死亡率;检测各组大鼠于Mtb攻毒前和Mtb攻毒后1、2、3、5个月末的外周血中CD3⁺、CD4⁺、CD8⁺、DPT细胞含量,第2、5个月末加查淋巴细胞绝对计数。结果(1)Mtb感染后1个月内1、3、4组各死亡2只大鼠,第2组死亡1只大鼠。化疗开始后4个月治疗期死亡率:化疗一开始即同步加BCG治疗组22.2%(4/18)高于化疗1月后加BCG治疗组(0/19),P<0.05;化疗对照组为5.6%(1/18),(2)结核病鼠表现为CD4/CD8比值(可伴CD4⁺细胞)降低、CD8⁺(可伴DP)细胞升高,P<0.05或P<0.01;这种改变可在化疗后1-2个月内恢复到接近正常水平。(3)化疗开始同步加用BCG组治疗1个月时表现为T淋巴细胞(CD3⁺)、CD4⁺T细胞百分率显著降低,而淋巴细胞绝对计数和CD8⁺、DPT细胞百分率升高,P<0.05或P<0.01;治疗2个月后CD3⁺、CD4⁺T细胞恢复到正常范围而仍保持CD8⁺、DPT细胞较高水平。(4)化疗1个月后再加用BCG组在加用BCG后表现为CD3⁺、CD4⁺细胞百分率不降低而CD8⁺、DP细胞升高。结论淋巴细胞总数显著升高而T细胞占总淋巴细胞百分率显著降低是化疗开始同步加BCG治疗组第一个月死亡率升高的一个重要免疫学特征。DP细胞是抗结核保护性免疫相关细胞。BCG作结核病的免疫治疗应在化疗1个月后开始。     

紫外线减毒弓形虫ZS1株滋养体在小鼠体内的细胞免疫反应

目的： 探讨紫外线减毒弓形虫ＺＳ１ 株在小鼠体内的免疫保护性和细胞免疫反应。方法： 用波长为２５３７°Ａ 的紫外线照射弓形虫ＺＳ１株滋养体, 照射高度为５ ｃｍ , 照射时间６０ ｍ ｉｎ。小鼠于免疫后４５ ｄ 用同株滋养体攻击感染, 攻击后４ ｄ 剖杀, 与单免疫组、单感染组及正常对照组小鼠比较其脾Ｔ淋巴细胞增殖反应及其亚群的变化。结果： 小鼠接种紫外线减毒弓形虫ＺＳ１ 株滋养体后能正常存活, 于接种后４９ ｄ 各组织未查见滋养体、包囊或假包囊; 免疫组攻击感染后存活时间较单感染组延长; 体外特异抗原刺激后, 可诱导免疫组及免疫攻击组强的脾Ｔ淋巴细胞增殖反应; 免疫攻击组ＣＤ４＋ Ｔ细胞明显下降, ＣＤ４＋ ／ＣＤ８＋ 比率倒置; 免疫组、免疫攻击组及感染组的ＮＫ细胞活性均明显增强。结论： 紫外线减毒弓形虫ＺＳ１株滋养体疫苗能够诱导免疫小鼠产生一定的抗攻击感染保护力, 其中ＣＤ８＋ Ｔ细胞和ＮＫ细胞可能发挥着重要作用。     

胸腺肽α1对高龄患者消化系统肿瘤的临床效果研究

目的 研究胸腺肽α1对高龄消化系统恶性肿瘤患者的临床疗效.方法 选取湖北省黄岗市中心医院2010年2月-2012年6月收治的192例临床资料较为完整的老年消化系统肿瘤患者作为研究对象,随机分为对照组和治疗组,每组96例.对对照组进行化疗,同时皮下注射生理盐水,116 mg/次,每2d一次,连续治疗8周;对治疗组进行化疗,同时皮下注射胸腺肽α1,116mg/次,每2d一次,连续治疗8周.对所有患者进行T细胞亚群和NK淋巴细胞活性监测,监测时间为治疗前1周和治疗第2、4、8周,同时对比治疗前后两组患者的体力情况,进行Karnofsky评分比较.结果 治疗前,治疗组与对照组各免疫指标差异均无统计学意义（P＞0.05）.治疗后,治疗组CD4＋、CD4＋/CD8＋和NK淋巴细胞指标明显高于对照组,差异均有统计学意义（P均＜0.05）;CD3＋ 、CD8＋指标差异均无统计学意义（P均＞0.05）.治疗组治疗后CD4＋、CD4＋/CD8＋和NK淋巴细胞指标明显高于治疗前,差异有统计学意义（P＜0.05）.治疗前后对所有患者进行Karnofsky评分比较,治疗后治疗组平均评分明显高于对照组,差异有统计学意义（P＜0.05）;所有患者体力情况随治疗时间延长均有所下降,对照组患者治疗前后评分比较差异有显著统计学意义（P＜0.01）.结论 胸腺肽α1对提高患者的免疫指数具有显著效果,对患者体力下降的情况具有明显的抑制作用,对高龄患者消化系统肿瘤的临床效果显著.